Counterpoint Mutual Funds
CSTL icon

Counterpoint Mutual Funds’s Castle Biosciences CSTL Stock Holding History

Counterpoint Mutual Funds’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-16,510
Closed -$394K – 361
2026
Q2 		$394K Buy
+16,510
New +$368K 0.04% 195
2026
Q1 		– Sell
-12,952
Closed -$504K – 338
2025
Q4 		$504K Buy
+12,952
New +$418K 0.04% 128
2025
Q1 		– Sell
-13,587
Closed -$362K – 316
2024
Q4 		$362K Buy
13,587
+4,688
+53% +$143K 0.05% 179
2024
Q3 		$254K Buy
+8,899
New +$226K 0.05% 212

Other funds holding CSTL

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
FBT
First Bank & Trust Brookings, South Dakota $687M AUM 18.35% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Oak Harvest Investment Services
Oak Harvest Investment Services Houston, Texas $1.07B AUM 32.83% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Counterpoint Mutual Funds's CSTL Position: Q3 2026 in Review

Counterpoint Mutual Funds sold out of Castle Biosciences (CSTL) in Q3 2026, closing a stake of 16,510 shares — an estimated $394K sold.

Counterpoint Mutual Funds first reported a position in CSTL in Q3 2024 and held it in 4 quarters. The position peaked at $504K in Q4 2025. 14 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Counterpoint Mutual Funds reported no remaining Castle Biosciences position as of Q3 2026 after selling out during the quarter.
  • Counterpoint Mutual Funds sold 16,510 Castle Biosciences shares in Q3 2026, an estimated $394K.
  • Counterpoint Mutual Funds first reported a position in Castle Biosciences in Q3 2024 and held it in 4 quarters.
  • Counterpoint Mutual Funds's Castle Biosciences position peaked at $504K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Counterpoint Mutual Funds's 13F filing for Q3 2026, filed 16 Oct 2026.